Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese CRO Support Firm SRD Acquires Expartner Japan

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Japanese contract research organization support company SRD acquires Expartner Japan, a Tokyo-based consulting company for outsourcing medical devices and related regulatory affairs. SRD has acquired 80 percent of EPJ shares. Through the acquisition, SRD hopes to develop a synergy by combining EPJ's expertise in medical devices, related regulatory affairs and approval application support, with its own business in CRO and site management organization support, as well as good laboratory practices testing facilities. According to SRD, the company hopes the synergy will bear fruit to a whole process support system to serve both domestic and overseas medical device makers. Along with a strengthened device support business, SRD also plans to enter the regenerative medicine support business area. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel